Figure 3 | Scientific Reports

Figure 3

From: Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis

Figure 3

Serum cfDNA levels decreased with therapy in r-axSpA patients until 3 months from baseline. (a) Serum cfDNA levels were higher in the validation cohort at diagnosis than in healthy controls (HC). (b) Serum cfDNA levels decreased in all 51 patients after treatment. (c) Serum cfDNA levels in patients treated with NSAIDs alone after treatment. (d) Serum cfDNA levels decreased in patients treated with NSAIDs + DMARDs after treatment. (e) Serum cfDNA levels decreased in patients treated with NSAIDs + TNFi after treatment. (f) Serum cfDNA levels decreased in the responders group after treatment. (g) cfDNA levels in the non-responders group were not significantly reduced after treatment. (h) cfDNA levels fell with treatment containing DMARDs or TNFi but not NSAIDs alone in the responders group. (i) cfDNA levels in the non-responders group were not significantly reduced in any of the treatment groups. (j–k) Serum levels of cfDNA, CRP and ESR after treatment in the responders group and the non-responders group. Each data point represents a separate case. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 and ns not significant.

Back to article page